

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>			
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		Application Number	10/531,049		
		Filing Date	§ 371 Date: January 17, 2006		
		First Named Inventor	LIANG, Jingyu		
		Art Unit	<del>7015</del> 1621		
		Examiner Name	KEYS, Rosalyn Ann		
Sheet	1	of	1	Attorney Docket Number	2108.0060000/MAC/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL10	"Inositol," The Merck Index, Thirteenth Edition, Merck & Co., Inc., Whitehouse Station, N.J., Monograph No. 5001, 1 page (October, 2001)	
	NPL11	IUPAC Commission on the Nomenclature of Organic Chemistry (CNOC) and IUPAC-IUB Commission on Biochemical Nomenclature (CBN), "Nomenclature of Cyclitols," <i>Pure Appl. Chem.</i> 37:285-297, Butterworths (1974)	
	NPL12	Preziosi, P., <i>et al.</i> , "Effects of Single or Repeated Treatment with Several Anticholesterolemic Compounds on Biliary Excretion of Cholesterol," <i>Biochemical Pharmacology</i> 5:251-262, Pergamon Press Ltd. (1960)	
	NPL13	Zhan, T. and Lou, H., "Synthesis of azole nucleoside analogues of D-pinitol as potential antitumor agents," <i>Carbohydrate Research</i> 342:865-869, Elsevier Science Ltd. (May, 2007)	

757451\_1

Examiner Signature	/Rosalyn Keys/	Date Considered	05/10/2008
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 805. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RK/